诺和诺德品牌精简更名“Novo”应对减肥药竞争Novo Nordisk Rebrands as 'Novo' Amid Weight-Loss Drug Competition
丹麦制药商诺和诺德于2026年9月14日宣布将其品牌名称简化为“Novo”，并同步更新公牛标识及企业文化准则，不过其法定公司名称仍将保留为Novo Nordisk。该项品牌重塑计划围绕口号“持久健康始于当下”展开，旨在应对日益以消费者为导向的市场环境。首席执行官Mike Doustdar指出，过去数年间涌现出大量仅希望减重而非将自身视作传统胰岛素患者的消费群体。面对主要竞争对手礼来的激烈竞争，根据礼来财报引用的IQVIA数据，第二季度诺和诺德在肥胖药物市场的份额降至38.8%，落后于礼来的60.9%。尽管诺和诺德股价今年已下跌约15%且近期终止了三项试验性心血管药物研发，但口服版Wegovy已在美国推出并在欧洲获批，处方量突破300万张。公司定于9月21日的资本市场日详细说明其长期业务战略调整。
Danish pharmaceutical maker Novo Nordisk announced on September 14, 2026, that it is rebranding its name to 'Novo' and updating its bull packaging logo alongside corporate culture guidelines, while retaining Novo Nordisk as its legal corporate name. The overhaul is anchored by the phrase 'Lasting Health Starts Now,' reflecting an effort to adapt to an increasingly consumer-driven weight-loss market. Chief Executive Officer Mike Doustdar explained that the company is responding to a growing demographic seeking weight loss without viewing themselves as conventional medical patients. The move arrives as Novo battles mounting pressure from chief rival Eli Lilly, which held a 60.9% obesity market share in the second quarter compared with Novo's 38.8%, according to a Lilly earnings presentation citing IQVIA data. Although Novo's shares have fallen about 15% this year following the termination of three experimental cardiovascular trials, the company has gained momentum with its oral Wegovy tablet, which has surpassed 3 million prescriptions. Executives plan to outline the company's broader business and commercial strategy at its Capital Markets Day on September 21.
01品牌精简：更名“Novo”与直面消费者转型Brand Streamlining: Shortening to 'Novo' and Direct-to-Consumer Shift
根据公司发布的重塑方案，该药企在产品包装上启用简化后的“Novo”标识以及重新设计的公牛图案，旨在增强品牌在客户群体中的辨识度与相关性。公司的法定全称仍将维持1989年由Novo Terapeutisk Laboratorium与Nordisk Insulinlaboratorium合并确立的Novo Nordisk不变。
Under the rebranding rollout, the Danish drugmaker is introducing the streamlined 'Novo' name alongside an updated version of its corporate bull logo across product packaging to make the brand more memorable and relevant to end users. The company's full legal corporate name remains Novo Nordisk, preserving a designation that originates from the 1989 merger between Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium.
首席执行官Mike Doustdar在接受丹麦TV2电视台采访时表示，调整品牌是重塑企业形象的关键举措。他指出，传统使用胰岛素的人群通常被归类为患者，但在过去四到五年间，越来越多消费者明确表达自身并未患病、仅希望减轻体重的诉求，促使公司加快向直面消费者的业务模式转型。
Chief Executive Officer Mike Doustdar told Denmark's TV2 television that the strategic overhaul is part of a broader effort to reinvent the organization for a direct-to-consumer landscape. Doustdar stated that while traditional insulin users have historically identified as medical patients, the past four to five years have seen a rapidly expanding demographic that does not consider itself ill and seeks treatments strictly for weight reduction.
02市场压力：份额落后于礼来与资本市场预期Market Headwinds: Trailing Eli Lilly in Obesity Market Share
在肥胖药物领域，诺和诺德正承受来自竞争对手礼来的严峻市场压力。礼来财报所引用的IQVIA数据显示，第二季度诺和诺德在肥胖治疗市场的份额已下滑至38.8%，而礼来则占据了60.9%的市场份额。此外，由于近期终止了三项针对试验性心血管药物的临床试验，诺和诺德的股价在今年累计下跌约15%。
Novo is confronting substantial commercial pressure in the anti-obesity sector from its primary rival, Eli Lilly. According to a Lilly earnings presentation citing IQVIA data, Novo's market share in the obesity treatment category stood at 38.8% during the second quarter, while Lilly captured a commanding 60.9% share. Alongside that competitive lag, shares of Novo have dropped approximately 15% this year after the drugmaker recently scrapped three clinical trials on an experimental cardiovascular drug.
面对投资者要求推出重磅创新产品并开辟长期增长路径的诉求，该药企计划在9月21日举行的资本市场日活动中，向外界系统阐述其业务战略调整与商业规划，以应对更加快速且竞争激烈的市场环境。
The operational setbacks and trailing market numbers have intensified investor demands for the Danish company to deliver new blockbuster products and define a sustainable path toward long-term growth. Novo plans to detail its updated business strategy and organizational roadmap during its Capital Markets Day presentation scheduled for September 21, addressing a faster, more competitive, and increasingly consumer-focused marketplace.
诺和诺德品牌演变与减重药竞争历程Timeline of Novo Nordisk's Brand Evolution and Market Competition
梳理诺和诺德公司名称渊源、减重药商业进展及应对竞争实施品牌重塑的关键节点。
Traces the origins of Novo Nordisk's corporate identity, obesity market competition, and the decisions leading to its 2026 rebranding.
诺和治疗实验室与诺德胰岛素实验室合并成立诺和诺德公司，奠定了该集团长期使用的法定全称及双重业务传统。
Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium merged to create Novo Nordisk, establishing the company's long-standing legal corporate name.
诺和诺德在美国推出口服版减重药物Wegovy片剂，抢占非注射类减重疗法市场先机，该药随后也在欧洲获批上市。
Novo Nordisk launched its new oral Wegovy tablet in the United States to capture market share in non-injectable anti-obesity treatments, followed by approval in Europe.
口服Wegovy在美处方量突破300万张。然而礼来二季度减重药市场份额攀升至60.9%，诺和诺德以38.8%落后，加之试验受挫导致股价承压。
Oral Wegovy prescriptions surpassed 3 million in the US, but Novo's second-quarter obesity market share fell to 38.8% against Eli Lilly's 60.9%, adding to commercial pressure.
诺和诺德宣布将品牌名称简化为“Novo”并更新包装标识，发布“持久健康始于当下”口号与文化准则，以全面适应日益由消费者主导的市场。
Novo Nordisk announced it is rebranding to 'Novo' with an updated logo, new slogan, and revised corporate culture principles to adapt to a consumer-driven obesity market.
03文化与战略：四大准则与“持久健康始于当下”口号Corporate Culture and Strategy: Four Principles and New Slogan
在更名的同时，Novo公布了以“持久健康始于当下”为核心的全新品牌口号。该公司表示，这一营销宣传倡导患者应立即而非推迟采取行动以实现长期健康目标，旨在建立与公众及各利益相关方的信任和关联，进而让突破性科学成果更贴近大众的日常生活。
Alongside its refreshed brand identity, Novo introduced a global marketing campaign centered on the slogan 'Lasting Health Starts Now.' According to the company's release, the messaging promotes the concept that patients should begin making tangible progress toward long-term physical well-being immediately rather than delaying treatment. The drugmaker described the strategic initiative as an effort to build deeper relevance and trust among the general public and external stakeholders, aiming to bring breakthrough scientific innovations closer to everyday life.
为配合业务向直面消费者渠道拓展，该药企确立了四项新的企业文化准则，以期在竞争加剧的市场中构建运营优势。这些准则包括：以患者为核心开展创新研发、提升公司业绩以“为所有利益相关方创造更大价值”、制定更明确的优先事项并精简工作流程，以及在患者安全与道德伦理方面绝不妥协。
To support this commercial evolution as more of its pharmaceutical products shift toward direct-to-consumer distribution, Novo established a new framework consisting of four core cultural principles designed to secure operational advantages. These tenets require the organization to innovate with patients as the primary focus, elevate overall corporate performance to create greater value for all stakeholders, establish clearer priorities with simplified internal workflows, and maintain an absolute commitment to never compromising on patient safety and business ethics.
04产品支柱：口服Wegovy的市场进展与区域拓展Product Momentum: Oral Wegovy Growth and Regional Expansion
在各项业务挑战之中，口服版Wegovy片剂的推出成为Novo今年重要的业务支撑。该口服药于1月在美国市场正式发布，截至6月其处方量已经突破300万张，呈现出强劲的市场增长势头。除美国市场外，该片剂近期也已获得欧洲监管机构的批准，进一步扩大了其地域覆盖范围。
Among its broader commercial challenges, the rollout of the oral Wegovy tablet has emerged as a significant operational tailwind for Novo this year. The Danish drugmaker introduced the new tablet form of Wegovy in the United States in January, and total prescriptions exceeded 3 million as of June. Alongside its North American uptake, the pill recently secured regulatory approval for use in Europe, broadening its geographic reach across key overseas markets.
口服Wegovy的迅速推广为该公司在减肥药领域确立了关键的时间优势。目前，礼来公司正在研发名为Foundayo的竞品减肥药片，而Novo通过口服Wegovy在美欧两地的率先上市与审批，在该类新兴口服制剂赛道中领先于礼来的产品布局。
The explosive uptake of the Wegovy tablet has provided Novo with an important head start in the evolving market for non-injectable anti-obesity treatments. The company's chief competitor, Eli Lilly, is currently developing a rival weight-loss pill named Foundayo, allowing Novo to establish a commercial lead in the oral category as it works to defend and expand its position across the obesity sector.
